JP2017531019A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017531019A5 JP2017531019A5 JP2017520471A JP2017520471A JP2017531019A5 JP 2017531019 A5 JP2017531019 A5 JP 2017531019A5 JP 2017520471 A JP2017520471 A JP 2017520471A JP 2017520471 A JP2017520471 A JP 2017520471A JP 2017531019 A5 JP2017531019 A5 JP 2017531019A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- hydrogen
- alkyl
- item
- carbocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims description 108
- 239000001257 hydrogen Substances 0.000 claims description 108
- 150000001875 compounds Chemical class 0.000 claims description 104
- 125000000217 alkyl group Chemical group 0.000 claims description 84
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 59
- 150000002431 hydrogen Chemical class 0.000 claims description 43
- 125000006706 (C3-C6) carbocyclyl group Chemical group 0.000 claims description 40
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 40
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 34
- 125000000623 heterocyclic group Chemical group 0.000 claims description 25
- 150000003839 salts Chemical class 0.000 claims description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 21
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 17
- 229910052736 halogen Inorganic materials 0.000 claims description 16
- 150000002367 halogens Chemical class 0.000 claims description 16
- 125000001072 heteroaryl group Chemical group 0.000 claims description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
- 125000003118 aryl group Chemical group 0.000 claims description 12
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 10
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 10
- 208000005809 status epilepticus Diseases 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 150000001721 carbon Chemical group 0.000 claims description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 8
- 206010039897 Sedation Diseases 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 230000036280 sedation Effects 0.000 claims description 6
- 206010002091 Anaesthesia Diseases 0.000 claims description 5
- 206010010904 Convulsion Diseases 0.000 claims description 5
- 230000037005 anaesthesia Effects 0.000 claims description 5
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical group NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 4
- 206010015037 epilepsy Diseases 0.000 claims description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 13
- 238000000034 method Methods 0.000 description 27
- 208000035475 disorder Diseases 0.000 description 16
- 210000003169 central nervous system Anatomy 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 238000012360 testing method Methods 0.000 description 3
- 206010006550 Bulimia nervosa Diseases 0.000 description 2
- 206010053398 Clonic convulsion Diseases 0.000 description 2
- 208000030814 Eating disease Diseases 0.000 description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 description 2
- 208000026139 Memory disease Diseases 0.000 description 2
- 208000019022 Mood disease Diseases 0.000 description 2
- 208000016285 Movement disease Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 208000009205 Tinnitus Diseases 0.000 description 2
- 206010043994 Tonic convulsion Diseases 0.000 description 2
- 206010048010 Withdrawal syndrome Diseases 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 208000029560 autism spectrum disease Diseases 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 235000014632 disordered eating Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 208000022821 personality disease Diseases 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 201000009032 substance abuse Diseases 0.000 description 2
- 231100000736 substance abuse Toxicity 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 231100000886 tinnitus Toxicity 0.000 description 2
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 description 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- DDZGQYREBDXECY-UHFFFAOYSA-N 1h-pyrazolo[3,4-b]pyrazine Chemical compound C1=CN=C2C=NNC2=N1 DDZGQYREBDXECY-UHFFFAOYSA-N 0.000 description 1
- CJGGKSPGRJHZNP-UHFFFAOYSA-N 2h-triazolo[4,5-b]pyrazine Chemical compound C1=CN=C2NN=NC2=N1 CJGGKSPGRJHZNP-UHFFFAOYSA-N 0.000 description 1
- 208000009575 Angelman syndrome Diseases 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- 238000010152 Bonferroni least significant difference Methods 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- HAIHKTYPNXBIGL-XHMYYXPFSA-N CC(CC1)([C@@H](CC2)C(C)(CC3)[C@H]1C(C)(CC1)C3C[C@]1(C)O)[C@H]2C(C[n](nc1)nc1C#N)=O Chemical compound CC(CC1)([C@@H](CC2)C(C)(CC3)[C@H]1C(C)(CC1)C3C[C@]1(C)O)[C@H]2C(C[n](nc1)nc1C#N)=O HAIHKTYPNXBIGL-XHMYYXPFSA-N 0.000 description 1
- LLZJVMWMJJGEFG-IMCDGWDMSA-N CC(CC1)([C@@H](CC2)C(CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(C[n]1ncc2c1cnc(F)c2)=O Chemical compound CC(CC1)([C@@H](CC2)C(CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(C[n]1ncc2c1cnc(F)c2)=O LLZJVMWMJJGEFG-IMCDGWDMSA-N 0.000 description 1
- QYTPCPDYQFOPTA-NTGRCJFGSA-N CC(CC1)([C@@H](CC2)C(CC3)[C@H]1[C@@](C)(CC1)[C@H]3C[C@]1(C)O)[C@H]2C(C[n](nc1)nc1C(O)=O)=O Chemical compound CC(CC1)([C@@H](CC2)C(CC3)[C@H]1[C@@](C)(CC1)[C@H]3C[C@]1(C)O)[C@H]2C(C[n](nc1)nc1C(O)=O)=O QYTPCPDYQFOPTA-NTGRCJFGSA-N 0.000 description 1
- JHGUGEQJDQPWIF-UCKIMXEFSA-N CC(CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@H]3C[C@]1(C)O)[C@H]2C(CN(/C=C(/C#N)\N)N)=O Chemical compound CC(CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@H]3C[C@]1(C)O)[C@H]2C(CN(/C=C(/C#N)\N)N)=O JHGUGEQJDQPWIF-UCKIMXEFSA-N 0.000 description 1
- OQRGNSGDDMIKMA-CMHYYJLDSA-N CC(CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@H]3C[C@]1(C)O)[C@H]2C(C[n](nc1)nc1C(N=N)=O)=O Chemical compound CC(CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@H]3C[C@]1(C)O)[C@H]2C(C[n](nc1)nc1C(N=N)=O)=O OQRGNSGDDMIKMA-CMHYYJLDSA-N 0.000 description 1
- GXEQUNVRCPJRKN-UHFFFAOYSA-O CC(CC1)CC(CC2)C1(C)C(CC1)C2C(CC2)C1(C)C2C(CN(C=C(CO)[NH3+])N)=O Chemical compound CC(CC1)CC(CC2)C1(C)C(CC1)C2C(CC2)C1(C)C2C(CN(C=C(CO)[NH3+])N)=O GXEQUNVRCPJRKN-UHFFFAOYSA-O 0.000 description 1
- QZZBOGAACWFQLY-QLJYGYJRSA-N CCOC(c1c[n](CC([C@@H](CC2)C(C)(CC3)C2C(CC2)C3[C@]3(C)C2C[C@@H](C)CC3)=O)nn1)=O Chemical compound CCOC(c1c[n](CC([C@@H](CC2)C(C)(CC3)C2C(CC2)C3[C@]3(C)C2C[C@@H](C)CC3)=O)nn1)=O QZZBOGAACWFQLY-QLJYGYJRSA-N 0.000 description 1
- ZSCZDGHVWZYGHP-CIBAILGSSA-N CCOC(c1n[n](CC([C@@H](CC2)[C@@](C)(CC3)[C@@H]2C(CC2)[C@H]3[C@]3(C)C2C[C@@H](C)CC3)=O)nc1)=O Chemical compound CCOC(c1n[n](CC([C@@H](CC2)[C@@](C)(CC3)[C@@H]2C(CC2)[C@H]3[C@]3(C)C2C[C@@H](C)CC3)=O)nc1)=O ZSCZDGHVWZYGHP-CIBAILGSSA-N 0.000 description 1
- NXTMGPCZTVQYDR-QJFXUDICSA-N C[C@@H](CC1)CC(CC2)[C@@]1(C)C(CC1)[C@@H]2C(CC2)[C@@]1(C)[C@H]2C(CN/C=C(\C=N)/SC)=O Chemical compound C[C@@H](CC1)CC(CC2)[C@@]1(C)C(CC1)[C@@H]2C(CC2)[C@@]1(C)[C@H]2C(CN/C=C(\C=N)/SC)=O NXTMGPCZTVQYDR-QJFXUDICSA-N 0.000 description 1
- BYTORSQJJQPHEP-OKBVTIHDSA-N C[C@@H](CC1)CC(CC2)[C@@]1(C)C(CC1)[C@@H]2C(CC2)[C@@]1(C)[C@H]2C(CNc(c(N)ccc1Cl)c1F)=O Chemical compound C[C@@H](CC1)CC(CC2)[C@@]1(C)C(CC1)[C@@H]2C(CC2)[C@@]1(C)[C@H]2C(CNc(c(N)ccc1Cl)c1F)=O BYTORSQJJQPHEP-OKBVTIHDSA-N 0.000 description 1
- MMSNEIDBQQOVNQ-MBZAPRSTSA-N C[C@@H](CC1)CC(CC2)[C@@]1(C)C(CC1)[C@@H]2C(CC2)[C@@]1(C)[C@H]2C(C[n](cc1)nc1N)=O Chemical compound C[C@@H](CC1)CC(CC2)[C@@]1(C)C(CC1)[C@@H]2C(CC2)[C@@]1(C)[C@H]2C(C[n](cc1)nc1N)=O MMSNEIDBQQOVNQ-MBZAPRSTSA-N 0.000 description 1
- WLIKIIPCEFCJMM-RFOUXBABSA-N C[C@@H](CC1)CC(CC2)[C@@]1(C)C(CC1)[C@@H]2C(CC2)[C@@]1(C)[C@H]2C(C[n]1nc(cccc2)c2n1)=O Chemical compound C[C@@H](CC1)CC(CC2)[C@@]1(C)C(CC1)[C@@H]2C(CC2)[C@@]1(C)[C@H]2C(C[n]1nc(cccc2)c2n1)=O WLIKIIPCEFCJMM-RFOUXBABSA-N 0.000 description 1
- QIGVVLATEKONOQ-RFOUXBABSA-N C[C@@H](CC1)CC(CC2)[C@@]1(C)C(CC1)[C@@H]2C(CC2)[C@@]1(C)[C@H]2C(C[n]1nnc2c1cccc2)=O Chemical compound C[C@@H](CC1)CC(CC2)[C@@]1(C)C(CC1)[C@@H]2C(CC2)[C@@]1(C)[C@H]2C(C[n]1nnc2c1cccc2)=O QIGVVLATEKONOQ-RFOUXBABSA-N 0.000 description 1
- WBZRPIJQNHHMCX-CDHQNFADSA-N C[C@](CC1)([C@@H](CC2)C(CC3)[C@H]1[C@@](C)(CC1)[C@H]3C[C@]1(C)O)[C@H]2C(C[n]1nc(CO)cn1)=O Chemical compound C[C@](CC1)([C@@H](CC2)C(CC3)[C@H]1[C@@](C)(CC1)[C@H]3C[C@]1(C)O)[C@H]2C(C[n]1nc(CO)cn1)=O WBZRPIJQNHHMCX-CDHQNFADSA-N 0.000 description 1
- YSOGXLDURSYIFU-RYYSEAFRSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(CN(c(c(N)ccc1)c1OC)N)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(CN(c(c(N)ccc1)c1OC)N)=O YSOGXLDURSYIFU-RYYSEAFRSA-N 0.000 description 1
- BKFNKYNHUJBBNZ-RYYSEAFRSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(CN1NNc2c1cccc2OC)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(CN1NNc2c1cccc2OC)=O BKFNKYNHUJBBNZ-RYYSEAFRSA-N 0.000 description 1
- HRCKJXMCKAJWLD-MWJJQOQKSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(C[n](c1c2)nnc1cc(F)c2F)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(C[n](c1c2)nnc1cc(F)c2F)=O HRCKJXMCKAJWLD-MWJJQOQKSA-N 0.000 description 1
- OELNQUAOUXMFIA-IRTDTLKWSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(C[n]1c(C)cnc1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(C[n]1c(C)cnc1)=O OELNQUAOUXMFIA-IRTDTLKWSA-N 0.000 description 1
- JBFQDUDMHFOOHY-IRTDTLKWSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(C[n]1cnc(C)c1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(C[n]1cnc(C)c1)=O JBFQDUDMHFOOHY-IRTDTLKWSA-N 0.000 description 1
- BHHMQSIQBUEIDS-RRUSVTLESA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(C[n]1nc(ccc(Cl)c2)c2c1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(C[n]1nc(ccc(Cl)c2)c2c1)=O BHHMQSIQBUEIDS-RRUSVTLESA-N 0.000 description 1
- FDGQNFUIUFQVSQ-HMIRPSGWSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(C[n]1nc(cnc(F)c2)c2c1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(C[n]1nc(cnc(F)c2)c2c1)=O FDGQNFUIUFQVSQ-HMIRPSGWSA-N 0.000 description 1
- NDGPXCWCZHNFLX-RYYSEAFRSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(C[n]1nc2c(OC)cccc2n1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(C[n]1nc2c(OC)cccc2n1)=O NDGPXCWCZHNFLX-RYYSEAFRSA-N 0.000 description 1
- QYJGPUZMQLHUGI-FEWIBYRGSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(C[n]1ncc(Cl)c1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(C[n]1ncc(Cl)c1)=O QYJGPUZMQLHUGI-FEWIBYRGSA-N 0.000 description 1
- SLRWCUJLNSUTTQ-RRUSVTLESA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(C[n]1ncc(cc2)c1cc2Cl)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(C[n]1ncc(cc2)c1cc2Cl)=O SLRWCUJLNSUTTQ-RRUSVTLESA-N 0.000 description 1
- YQDPRFNRZGBIIK-RRUSVTLESA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(C[n]1ncc2c1ccc(Cl)c2)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(C[n]1ncc2c1ccc(Cl)c2)=O YQDPRFNRZGBIIK-RRUSVTLESA-N 0.000 description 1
- XRCJDOFKYPSPKG-JGANGFLVSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(C[n]1nncn1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(C[n]1nncn1)=O XRCJDOFKYPSPKG-JGANGFLVSA-N 0.000 description 1
- BRVGKZNQWCQKTC-MVCIVNJCSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(COC)O)[C@H]2C(C[n]1cncc1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(COC)O)[C@H]2C(C[n]1cncc1)=O BRVGKZNQWCQKTC-MVCIVNJCSA-N 0.000 description 1
- GXQLATSLKADNDP-VVXGJYLHSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(COC)O)[C@H]2C(C[n]1ncc(C#N)c1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(COC)O)[C@H]2C(C[n]1ncc(C#N)c1)=O GXQLATSLKADNDP-VVXGJYLHSA-N 0.000 description 1
- CUHBLEDQDCSGAV-GKWLLKCESA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(COC)O)[C@H]2C(C[n]1ncc(C(F)(F)F)c1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(COC)O)[C@H]2C(C[n]1ncc(C(F)(F)F)c1)=O CUHBLEDQDCSGAV-GKWLLKCESA-N 0.000 description 1
- ZWAWEBXHXJHQPG-VVXGJYLHSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(COC)O)[C@H]2C(C[n]1ncc(C)c1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(COC)O)[C@H]2C(C[n]1ncc(C)c1)=O ZWAWEBXHXJHQPG-VVXGJYLHSA-N 0.000 description 1
- JBFQDUDMHFOOHY-NUXUQGQESA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@H]3C[C@]1(C)O)[C@H]2C(C[n]1cnc(C)c1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@H]3C[C@]1(C)O)[C@H]2C(C[n]1cnc(C)c1)=O JBFQDUDMHFOOHY-NUXUQGQESA-N 0.000 description 1
- BGWXZANPYOXVTJ-WJXSLUJHSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@H]3C[C@]1(C)O)[C@H]2C(C[n]1ncc(C(F)(F)F)c1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@H]3C[C@]1(C)O)[C@H]2C(C[n]1ncc(C(F)(F)F)c1)=O BGWXZANPYOXVTJ-WJXSLUJHSA-N 0.000 description 1
- QYJGPUZMQLHUGI-WJXSLUJHSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@H]3C[C@]1(C)O)[C@H]2C(C[n]1ncc(Cl)c1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@H]3C[C@]1(C)O)[C@H]2C(C[n]1ncc(Cl)c1)=O QYJGPUZMQLHUGI-WJXSLUJHSA-N 0.000 description 1
- KVXOADAIUFPKKD-BVNVUKMXSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@H]3C[C@]1(C)O)[C@H]2C(C[n]1nnc(C(N)=O)c1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@H]3C[C@]1(C)O)[C@H]2C(C[n]1nnc(C(N)=O)c1)=O KVXOADAIUFPKKD-BVNVUKMXSA-N 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 238000011199 Dunnett post hoc test Methods 0.000 description 1
- 208000001914 Fragile X syndrome Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 201000009916 Postpartum depression Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 208000006289 Rett Syndrome Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000002566 clonic effect Effects 0.000 description 1
- 230000002920 convulsive effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000001037 epileptic effect Effects 0.000 description 1
- 208000028329 epileptic seizure Diseases 0.000 description 1
- 201000006517 essential tremor Diseases 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- OVCXRBARSPBVMC-UHFFFAOYSA-N triazolopyridine Chemical compound C=1N2C(C(C)C)=NN=C2C=CC=1C=1OC=NC=1C1=CC=C(F)C=C1 OVCXRBARSPBVMC-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462064961P | 2014-10-16 | 2014-10-16 | |
| US62/064,961 | 2014-10-16 | ||
| PCT/US2015/056054 WO2016061527A1 (en) | 2014-10-16 | 2015-10-16 | Compositions and methods for treating cns disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020086704A Division JP7012119B2 (ja) | 2014-10-16 | 2020-05-18 | Ｃｎｓ障害を処置するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017531019A JP2017531019A (ja) | 2017-10-19 |
| JP2017531019A5 true JP2017531019A5 (enExample) | 2018-11-29 |
| JP6909155B2 JP6909155B2 (ja) | 2021-07-28 |
Family
ID=55747445
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017520471A Active JP6909155B2 (ja) | 2014-10-16 | 2015-10-16 | Ｃｎｓ障害を処置するための組成物および方法 |
| JP2020086704A Active JP7012119B2 (ja) | 2014-10-16 | 2020-05-18 | Ｃｎｓ障害を処置するための組成物および方法 |
| JP2021175469A Active JP7455098B2 (ja) | 2014-10-16 | 2021-10-27 | Ｃｎｓ障害を処置するための組成物および方法 |
| JP2023032293A Active JP7692944B2 (ja) | 2014-10-16 | 2023-03-02 | Ｃｎｓ障害を処置するための組成物および方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020086704A Active JP7012119B2 (ja) | 2014-10-16 | 2020-05-18 | Ｃｎｓ障害を処置するための組成物および方法 |
| JP2021175469A Active JP7455098B2 (ja) | 2014-10-16 | 2021-10-27 | Ｃｎｓ障害を処置するための組成物および方法 |
| JP2023032293A Active JP7692944B2 (ja) | 2014-10-16 | 2023-03-02 | Ｃｎｓ障害を処置するための組成物および方法 |
Country Status (21)
| Country | Link |
|---|---|
| US (7) | US10577390B2 (enExample) |
| EP (3) | EP3206494A4 (enExample) |
| JP (4) | JP6909155B2 (enExample) |
| KR (2) | KR20230170816A (enExample) |
| CN (7) | CN117024502A (enExample) |
| AR (1) | AR102306A1 (enExample) |
| AU (5) | AU2015331749A1 (enExample) |
| BR (1) | BR112017007902B1 (enExample) |
| CA (1) | CA2964766A1 (enExample) |
| CO (1) | CO2017004649A2 (enExample) |
| IL (3) | IL291533B2 (enExample) |
| JO (1) | JO3724B1 (enExample) |
| MX (3) | MX2021004492A (enExample) |
| MY (1) | MY190408A (enExample) |
| NZ (1) | NZ769008A (enExample) |
| PE (1) | PE20170925A1 (enExample) |
| PH (2) | PH12021550427A1 (enExample) |
| RU (2) | RU2020131091A (enExample) |
| SG (3) | SG11201703073UA (enExample) |
| TW (3) | TWI762436B (enExample) |
| WO (1) | WO2016061527A1 (enExample) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2738526T3 (es) | 2011-10-14 | 2020-01-23 | Sage Therapeutics Inc | Compuestos 19-norpregnano 3,3-disustituidos, composiciones y usos de los mismos |
| IL275725B (en) | 2012-08-21 | 2022-08-01 | Sage Therapeutics Inc | Treatment methods for epilepsy and status epilepticus |
| US9725481B2 (en) | 2013-04-17 | 2017-08-08 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof |
| WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| RS60420B1 (sr) | 2013-04-17 | 2020-07-31 | Sage Therapeutics Inc | 19-nor neuroaktivni steroidi za metode lečenja |
| AU2014256229B2 (en) | 2013-04-17 | 2018-10-04 | Sage Therapeutics, Inc. | 19-nor C3,3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof |
| PL3021852T3 (pl) | 2013-07-19 | 2021-07-05 | Sage Therapeutics, Inc. | Neuroaktywne steroidy, kompozycje i ich zastosowania |
| JP6466942B2 (ja) | 2013-08-23 | 2019-02-06 | セージ セラピューティクス， インコーポレイテッド | 向神経活性ステロイド、組成物、及びその使用 |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| HUE051488T2 (hu) | 2014-10-16 | 2021-03-01 | Sage Therapeutics Inc | Készítmények és eljárások központi idegrendszeri rendellenességek kezelésére |
| WO2016061527A1 (en) | 2014-10-16 | 2016-04-21 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| US10774108B2 (en) | 2014-11-27 | 2020-09-15 | Sage Therapeutics, Inc. | Compositions and methods for treating CNS disorders |
| PL3250210T3 (pl) | 2015-01-26 | 2021-07-26 | Sage Therapeutics, Inc. | Kompozycje i sposoby leczenia zaburzeń OUN |
| JP6875996B2 (ja) | 2015-02-20 | 2021-05-26 | セージ セラピューティクス， インコーポレイテッド | 神経刺激性ステロイド、組成物、およびその使用 |
| RS62639B1 (sr) | 2015-07-06 | 2021-12-31 | Alkermes Inc | Hetero-halo inhibitori histonskih deacetilaza |
| EP3319968A1 (en) | 2015-07-06 | 2018-05-16 | Rodin Therapeutics, Inc. | Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase |
| ES2992037T3 (es) | 2016-07-11 | 2024-12-05 | Sage Therapeutics Inc | Esteroides neuroactivos sustituidos en C7, C12 y C16 y sus procedimientos de utilización |
| JP7049313B2 (ja) * | 2016-07-11 | 2022-04-06 | セージ セラピューティクス， インコーポレイテッド | Ｃ１７、ｃ２０、およびｃ２１置換神経刺激性ステロイドおよびそれらの使用方法 |
| NZ791594A (en) | 2016-08-23 | 2025-08-29 | Sage Therapeutics Inc | A crystalline 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroid |
| JP6756925B2 (ja) | 2017-01-11 | 2020-09-16 | ロダン・セラピューティクス，インコーポレーテッド | ヒストンデアセチラーゼの二環式阻害剤 |
| TWI620545B (zh) * | 2017-01-20 | 2018-04-11 | 長青生醫科技股份有限公司 | 生物參數量測方法及其裝置 |
| ES2914355T3 (es) | 2017-08-07 | 2022-06-09 | Alkermes Inc | Inhibidores bicíclicos de la histona desacetilasa |
| WO2019113494A1 (en) | 2017-12-08 | 2019-06-13 | Sage Therapeutics, Inc. | Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders |
| ES2991092T3 (es) * | 2017-12-22 | 2024-12-02 | Sage Therapeutics Inc | Compuestos 19-homo, 3-alfa-hidroxi-esteroides-20-ona para el tratamiento de trastornos del SNC |
| AR114044A1 (es) * | 2017-12-22 | 2020-07-15 | Sage Therapeutics Inc | Composiciones y métodos para el tratamiento de trastornos en el sistema nervioso central |
| ES3018614T3 (es) * | 2018-02-11 | 2025-05-16 | Jiangsu Hansoh Pharmaceutical Group Co Ltd | Reguladores derivados de esteroides, método para prepararlos y usos de los mismos |
| US10562930B1 (en) * | 2018-08-31 | 2020-02-18 | Praxis Precision Medicines, Inc. | Salts and crystal forms of GABAA positive allosteric modulator |
| US11634453B2 (en) * | 2018-10-12 | 2023-04-25 | Sage Therapeutics, Inc. | Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of CNS disorders |
| EP3867261B1 (en) * | 2018-10-19 | 2025-04-30 | Sage Therapeutics, Inc. | 9(11)-unsaturated neuroactive steroids and their methods of use |
| CN109369762B (zh) * | 2018-10-31 | 2021-06-18 | 湖南玉新药业有限公司 | 17-甲酸甾族化合物的制备方法 |
| CN109503694A (zh) * | 2018-11-21 | 2019-03-22 | 苏州闻天医药科技有限公司 | 一种新型gabaa受体调节剂及其用途 |
| TWI874337B (zh) | 2018-12-05 | 2025-03-01 | 美商賽吉醫療公司 | 神經活性類固醇及其使用方法 |
| AU2019397565A1 (en) * | 2018-12-14 | 2021-07-08 | Praxis Precision Medicines, Inc. | Methods for the treatment of depression |
| CN113226326B (zh) * | 2018-12-17 | 2024-09-20 | 细胞内治疗公司 | 有机化合物 |
| JP7692830B2 (ja) * | 2018-12-21 | 2025-06-16 | セージ セラピューティクス， インコーポレイテッド | ３α－ヒドロキシ－１７β－アミド神経刺激性ステロイドおよびその組成物 |
| EP3909967A4 (en) * | 2019-01-08 | 2022-11-09 | Chengdu Kanghong Pharmaceutical Co., Ltd. | STEROID COMPOUND AND USE THEREOF AND METHOD OF MANUFACTURE THEREOF |
| EP3934655A4 (en) * | 2019-03-04 | 2022-12-21 | Praxis Precision Medicines, Inc. | PERIMENOPAUSE AND MENOPAUSE TREATMENT METHODS |
| CR20240234A (es) * | 2019-05-31 | 2024-07-09 | Sage Therapeutics Inc | ESTEROIDES NEUROACTIVOS Y COMPOSICIONES DE ESTOS (Divisional 2021-629) |
| TWI896547B (zh) * | 2019-06-27 | 2025-09-11 | 美商賽吉醫療公司 | 用於治療cns病症之組合物及方法 |
| KR20220103707A (ko) * | 2019-09-30 | 2022-07-22 | 엘리엄 테라퓨틱스 (유케이) 엘티디 | Gabaa 수용체의 아형을 우선적으로 강화시키는 조성물 및 그의 사용 방법 |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| AU2020358002A1 (en) * | 2019-10-02 | 2022-04-21 | Praxis Precision Medicines, Inc. | Combinations of GABA-A receptor positive allosteric modulators and NMDA antagonists, NMDA negative allosteric modulators or NMDA partial agonists |
| WO2021168106A1 (en) * | 2020-02-18 | 2021-08-26 | Praxis Precision Medicines, Inc. | Deuterated neurosteroid |
| PE20221911A1 (es) * | 2020-03-25 | 2022-12-23 | Sage Therapeutics Inc | Uso de agentes para el tratamiento de condiciones respiratorias |
| US20230210870A1 (en) * | 2020-06-08 | 2023-07-06 | Eliem Therapeutics, Inc. | Methods of treating female health conditions related to sex hormones |
| WO2022006541A1 (en) * | 2020-07-02 | 2022-01-06 | Praxis Precision Medicines, Inc. | Methods for the treatment of adjustment disorder |
| WO2022040545A1 (en) * | 2020-08-20 | 2022-02-24 | Intra-Cellular Therapies, Inc. | Organic compounds |
| IT202000021316A1 (it) * | 2020-09-09 | 2022-03-09 | Ind Chimica Srl | PROCESSO PER LA PREPARAZIONE DI (3α,5α)-3-IDROSSI-3-METIL-PREGNAN-20-ONE (GANAXOLONE) |
| WO2022072620A1 (en) * | 2020-10-01 | 2022-04-07 | Eliem Therapeutics (UK) Ltd | Methods of treating fibromyalgia with neuroactive steroids |
| US20230372364A1 (en) * | 2020-10-01 | 2023-11-23 | Jeremy Hill | Method of treating gaba mediated disorders |
| WO2022177718A1 (en) | 2021-02-18 | 2022-08-25 | Sage Therapeutics, Inc. | Use of neuroactive steroid for treatment of sexual dysfunction |
| US20220296613A1 (en) * | 2021-03-19 | 2022-09-22 | Eliem Therapeutics (UK) Ltd | Food-independent dosing of cv-10155 to treat gabaa disorders |
| US20220296614A1 (en) * | 2021-03-19 | 2022-09-22 | Eliem Therapeutics (UK) Ltd | Dosing of cv-10155 in the evening or prior to sleep to treat gabaa disorders |
| CN117715641A (zh) * | 2021-04-26 | 2024-03-15 | 普拉西斯精密医药公司 | 用神经活性类固醇进行治疗的方法 |
| US20250170149A1 (en) | 2022-02-28 | 2025-05-29 | Sage Therapeutics, Inc. | Neuroactive steroids for treatment of gastrointestinal diseases or conditions |
| WO2023211856A1 (en) * | 2022-04-26 | 2023-11-02 | Praxis Precision Medicines, Inc. | Methods for the treatment of neurological disorders |
| CN115974950A (zh) * | 2022-12-23 | 2023-04-18 | 上海彩迩文生化科技有限公司 | 一种3-烷基化的甾体中间体及其制备和应用 |
| WO2024189061A1 (en) | 2023-03-14 | 2024-09-19 | Curia Spain, S.A.U. | Process and intermediates for the preparation of 3alpha-hydroxy-3beta-alkyl steroids |
| CN116574150A (zh) * | 2023-04-27 | 2023-08-11 | 广州楷石医药有限公司 | 一种二氢睾酮及其中间体的制备方法 |
| WO2024238387A1 (en) * | 2023-05-12 | 2024-11-21 | Nkmax Co., Ltd. | Method of treating alzheimer's disease with expanded natural killer cells |
Family Cites Families (121)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2856415A (en) | 1957-11-13 | 1958-10-14 | Searle & Co | 3,19-dihydroxy-5-androstene derivatives |
| FR1380417A (fr) | 1962-05-15 | 1964-12-04 | Roussel Uclaf | Nouveaux androstanyl-pyrazoles et procédé de préparation |
| US3206459A (en) | 1962-10-19 | 1965-09-14 | Syntex Corp | 10alpha-pregnan-19-ol derivatives |
| US3169134A (en) | 1963-03-21 | 1965-02-09 | Searle & Co | 2, 3-oxygenated-17alpha-methyl-5alpha-androstan-17beta-ols |
| BE754111A (fr) | 1969-07-29 | 1971-01-29 | Upjohn Co | Nouveaux 7alpha- et 7beta-methyl-3alpha,5alpha- cycloandrostanes et composes analogues 19-nor et leur procede de preparation |
| GB1434919A (en) | 1972-06-15 | 1976-05-12 | Glaxo Lab Ltd | 3alpha-hydroxy androstanes |
| GB1380246A (en) | 1970-12-17 | 1975-01-08 | Glaxo Lab Ltd | 3alpha-hydroxy-androstanes and esters thereof |
| US3943124A (en) | 1970-12-17 | 1976-03-09 | Gordon Hanley Phillipps | Chemical compounds |
| US3983111A (en) * | 1972-05-05 | 1976-09-28 | Glaxo Laboratories Limited | Steroidal anaesthetics of the pregnane and 19-norpregnane series |
| GB1430942A (en) | 1972-05-05 | 1976-04-07 | Glaxo Lab Ltd | 21-substituted 3alpha-hydroxy pregnanes |
| GB1436324A (en) * | 1972-05-12 | 1976-05-19 | Glaxo Lab Ltd | Anaesthetic 3alpha-hydroxy pregnanes |
| ES432106A1 (es) | 1973-11-30 | 1976-11-01 | Schering Ag | Procedimiento para la preparacion de d-homo-20-cetopregna- nos. |
| US4071625A (en) | 1974-05-13 | 1978-01-31 | Richardson-Merrell Inc. | 19-Oxygenated-5α-androstanes for the enhancement of libido |
| DE2438020A1 (de) | 1974-08-05 | 1976-02-26 | Schering Ag | 18-methyl-19-nor-20-keto-pregnane und verfahren zu ihrer herstellung |
| IL48628A0 (en) | 1974-12-23 | 1976-02-29 | Schering Ag | D-homo-20-keto-pregnanes and process for their manufactur |
| DE2526373C2 (de) | 1975-06-11 | 1983-11-10 | Schering AG, 1000 Berlin und 4709 Bergkamen | Verfahren zur Herstellung von Δ↑9↑↑(↑↑1↑↑1↑↑)↑-5α-20-Ketosteroiden |
| GB1570394A (en) | 1976-01-06 | 1980-07-02 | Glaxo Lab Ltd | 11-acyloxy-3-hydroxy steroids |
| US4192871A (en) | 1976-01-06 | 1980-03-11 | Glaxo Laboratories Limited | Chemical compounds |
| GB1581234A (en) | 1976-04-05 | 1980-12-10 | Glaxo Operations Ltd | 11a - amino - 3a - hydroxysteroids |
| DE2632677A1 (de) | 1976-07-16 | 1978-01-26 | Schering Ag | Verfahren zur herstellung von androstan-17-on-derivaten und deren verwendung |
| GB1581235A (en) | 1977-04-04 | 1980-12-10 | Glaxo Operations Ltd | 11a-amino-3a-hydroxy-steroids |
| US4389345A (en) | 1981-10-09 | 1983-06-21 | G.D. Searle & Co. | 3-Oxoestra-17-acetonitrile and unsaturated analogs |
| US4495102A (en) | 1982-09-03 | 1985-01-22 | G. D. Searle & Co. | Aminoalkyl steroids |
| US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| US5120723A (en) | 1987-08-25 | 1992-06-09 | University Of Southern California | Method, compositions, and compounds for modulating brain excitability |
| US5319115A (en) | 1987-08-25 | 1994-06-07 | Cocensys Inc. | Method for making 3α-hydroxy, 3β-substituted-pregnanes |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| WO1993005786A1 (en) | 1991-09-13 | 1993-04-01 | Cocensys, Inc. | Novel gabaa receptor with steroid binding sites |
| AU3075792A (en) | 1991-11-14 | 1993-06-15 | Stanley Poler | Secondary eye growth impeding device and method |
| DE4232681C2 (de) | 1992-09-29 | 1994-11-24 | Sigma Tau Ind Farmaceuti | 17-Phenyl- und 17-Furyl-14beta,5alpha-androstan- und androsten- Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzung |
| AU698834B2 (en) | 1993-05-24 | 1998-11-12 | Purdue Pharma Ltd. | Methods and compositions for inducing sleep |
| EP0656365B1 (en) | 1993-12-02 | 1997-04-09 | Akzo Nobel N.V. | Substituted 2beta-morpholinoandrostane derivatives |
| CZ300694A3 (en) | 1993-12-02 | 1996-05-15 | Akzo Nobel Nv | Substituted 2beta-morpholinandrostane derivatives, process of their preparation, their use for preparing pharmaceutical preparations and pharmaceutical compositions containing thereof |
| ATE195654T1 (de) * | 1994-02-14 | 2000-09-15 | Euro Celtique Sa | Androstane und pregnane zur allosterischen modulation des gaba-rezeptors |
| US5939545A (en) | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
| JP2002500616A (ja) | 1994-07-21 | 2002-01-08 | ファルマシア・アンド・アップジョン・カンパニー | 神経学的に活性なアミノステロイド |
| DE69519945T2 (de) | 1994-11-23 | 2001-06-07 | Cocensys, Inc. | Androstan- und pregnanserien für die allosterische modulation des gaba-rezeptors |
| KR19990022323A (ko) | 1995-06-06 | 1999-03-25 | 씨. 랜 낸시 | 안드로스탄 및 프레그난 시리즈의 신경활성 스테로이드 |
| WO1998005337A1 (en) * | 1996-08-01 | 1998-02-12 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| US5994334A (en) | 1997-02-05 | 1999-11-30 | University Of Maryland | Androgen synthesis inhibitors |
| US5935545A (en) | 1997-07-11 | 1999-08-10 | E. I. Du Pont De Nemours And Company | Process for producing an aqueous solution comprising ferric chloride |
| YU77701A (sh) * | 1999-04-29 | 2005-07-19 | Euro-Celtique S.A. | 3-α-HIDROKSI-3Гџ-METOKSIMETIL-21-HETEROCIKLIČNO SUPSTITUISANI STEROIDI SA ANESTETIČKIM DEJSTVOM |
| US7018406B2 (en) | 1999-11-17 | 2006-03-28 | Corevalve Sa | Prosthetic valve for transluminal delivery |
| ES2243442T3 (es) | 2000-02-18 | 2005-12-01 | Taiho Pharmaceutical Company Limited | Procedimiento de preparacion de derivados esteroides. |
| US6855836B2 (en) | 2000-10-26 | 2005-02-15 | Jenapharm Gmbh & Co. Kg | 17-Methylene steroids, process for their production and pharmaceutical compositions that contain these compounds |
| JP2004518637A (ja) | 2000-11-03 | 2004-06-24 | ワシントン・ユニバーシティ | 細胞保護活性を有する修飾されたヒドロキシ置換芳香族構造体 |
| GR1003861B (el) | 2000-12-29 | 2002-04-11 | Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa. | |
| AU2004224053B2 (en) | 2003-03-24 | 2011-06-09 | Sterix Limited | Oestrogen derivatives as inhibitors of steroid sulphatase |
| EP1626980A4 (en) | 2003-05-29 | 2007-07-04 | Univ Washington | NEUROACTIVE 13,24-CYCLO-18,21-DINORCHOLANES AND STRUCTURELY RELATED PENTACYCLIC STEROIDS |
| AU2004292555A1 (en) | 2003-11-24 | 2005-06-09 | Merck & Co., Inc. | Estrogen receptor modulators |
| WO2005105822A2 (en) * | 2004-04-23 | 2005-11-10 | Euro-Celtique S.A. | 3-alpha-hydroxy 21-n- heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof |
| US20060074059A1 (en) * | 2004-08-26 | 2006-04-06 | Goliber Philip A | Isomorphic crystalline habits of 3alpha-hydroxy-21-(1'-imidazolyl)-3beta-methoxymethyl-5alpha-pregnane-20-one |
| US8604011B2 (en) | 2004-09-27 | 2013-12-10 | The Regents Of The University Of California | Therapy for treatment of chronic degenerative brain diseases and nervous system injury |
| EP1807118B8 (en) | 2004-09-29 | 2014-04-23 | Harbor Therapeutics, Inc. | Steroid analogs and characterization and treatment methods |
| EP1888080B1 (en) * | 2005-06-09 | 2010-04-14 | Euro-Celtique S.A. | Pharmaceutical compositions of a neuroactive steroid and uses thereof |
| US20090203658A1 (en) | 2007-01-08 | 2009-08-13 | Duke University | Neuroactive steroid compositions and methods of use therefor |
| DE102007027636A1 (de) | 2007-06-12 | 2008-12-18 | Bayer Schering Pharma Aktiengesellschaft | 17ß-Cyano-18a-homo-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel |
| AU2008265898B2 (en) | 2007-06-15 | 2013-11-28 | Research Triangle Institute | Androstane and pregnane steroids with potent allosteric GABA receptor chloride ionophore modulating properties |
| GB0711948D0 (en) | 2007-06-20 | 2007-08-01 | Bionature E A Ltd | Neurosteriod compounds |
| CN101412742B (zh) | 2007-10-19 | 2013-07-31 | 天津金耀集团有限公司 | 一种抑制血管新生的硝酸酯药物 |
| US20090264443A1 (en) | 2008-04-18 | 2009-10-22 | David Helton | Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds |
| CN101624414B (zh) | 2008-07-07 | 2013-02-13 | 天津金耀集团有限公司 | 一种抑制血管新生的硝酸酯药物 |
| CZ2008434A3 (cs) | 2008-07-10 | 2009-12-09 | Ústav organické chemie a biochemie Akademie ved CR, v. v. i. | Pregnanové anionické slouceniny, zpusob jejich výroby a jejich použití |
| WO2010054158A2 (en) | 2008-11-07 | 2010-05-14 | Auspex Pharmaceuticals, Inc. | Steroid modulators of glucocorticoid receptor |
| WO2011079047A1 (en) | 2009-12-23 | 2011-06-30 | Drugtech Corporation | Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions |
| US20130303500A1 (en) | 2010-07-30 | 2013-11-14 | Medexis S.A. | Compounds and methods for treating neoplasia |
| WO2012083090A2 (en) | 2010-12-15 | 2012-06-21 | Harbor Biosciences, Inc. | Methods and compounds for preparing 3alpha-oxygen substituted steroids |
| CZ201181A3 (cs) | 2011-02-15 | 2012-09-12 | Ústav organické chemie a biochemie Akademie ved CR, v.v.i. | Deriváty pregnanolonu substituované v poloze 3alfa kationickou skupinou, zpusob jejich výroby, jejich použití a prostredek je obsahující |
| EP2675822A4 (en) | 2011-02-15 | 2014-07-30 | Socpra Sciences Et Génie S E C | STEROID ALKALOIDS AND THEIR USE AS ANTIMICROBIAL AGENTS AGAINST MICROORGANISMS WITH ELECTRON TRANSPORT FAILURE AND AS MICROBIAL AGENT EXHAUSTERS AGAINST PATHOGENIC BACTERIA |
| US9388210B2 (en) | 2011-02-25 | 2016-07-12 | Washington University | Neuroactive 17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
| EP2987866B1 (en) | 2011-03-23 | 2017-12-06 | Etsuro Ito | Method and kit for super-high-sensitivity measurement of protein and nucleic acid, and novel enzyme substrate |
| WO2013019711A2 (en) | 2011-07-29 | 2013-02-07 | The Regents Of The University Of California | NOVEL 17β-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS |
| CN107936076B (zh) | 2011-09-08 | 2021-10-15 | 萨奇治疗股份有限公司 | 神经活性类固醇、组合物、及其用途 |
| ES2738526T3 (es) | 2011-10-14 | 2020-01-23 | Sage Therapeutics Inc | Compuestos 19-norpregnano 3,3-disustituidos, composiciones y usos de los mismos |
| NZ773177A (en) | 2012-01-23 | 2022-09-30 | Sage Therapeutics Inc | Neuroactive steroid formulations and methods of treating cns disorders |
| WO2013188792A2 (en) | 2012-06-15 | 2013-12-19 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| NZ734451A (en) | 2012-06-19 | 2018-12-21 | Intercept Pharmaceuticals Inc | Preparation, uses and solid forms of obeticholic acid |
| WO2014028398A2 (en) | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids |
| IL275725B (en) | 2012-08-21 | 2022-08-01 | Sage Therapeutics Inc | Treatment methods for epilepsy and status epilepticus |
| US9765110B2 (en) | 2012-10-08 | 2017-09-19 | Washington University | Neuroactive 19-alkoxy-17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
| WO2014071449A1 (en) | 2012-11-09 | 2014-05-15 | Goodchild Investments Pty Ltd | Neuroactive steroids and their use to facilitate neuroprotection |
| JP6542127B2 (ja) | 2012-12-18 | 2019-07-10 | ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ | 向神経活性１９−アルコキシ−１７−置換ステロイド、そのプロドラッグおよびそれを使用する処置方法 |
| US8939545B2 (en) | 2012-12-20 | 2015-01-27 | Eastman Kodak Company | Inkjet printing with managed airflow for condensation control |
| CA2831054C (en) | 2013-01-09 | 2016-08-30 | Sapna Life Sciences Corp. | Formulations, and methods for their use in treatment of neuropathology and neurodegeneration as a result of traumatic injury |
| WO2014108808A2 (en) | 2013-01-09 | 2014-07-17 | Henry James Lorne | Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration |
| GB201302368D0 (en) | 2013-02-11 | 2013-03-27 | Univ Bath | Compound |
| US9512170B2 (en) | 2013-03-01 | 2016-12-06 | Washington University | Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors |
| US9562026B2 (en) | 2013-03-14 | 2017-02-07 | Washington University | Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors |
| RS60420B1 (sr) | 2013-04-17 | 2020-07-31 | Sage Therapeutics Inc | 19-nor neuroaktivni steroidi za metode lečenja |
| US9725481B2 (en) | 2013-04-17 | 2017-08-08 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof |
| WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| AU2014256229B2 (en) | 2013-04-17 | 2018-10-04 | Sage Therapeutics, Inc. | 19-nor C3,3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof |
| PL3021852T3 (pl) | 2013-07-19 | 2021-07-05 | Sage Therapeutics, Inc. | Neuroaktywne steroidy, kompozycje i ich zastosowania |
| JP6466942B2 (ja) | 2013-08-23 | 2019-02-06 | セージ セラピューティクス， インコーポレイテッド | 向神経活性ステロイド、組成物、及びその使用 |
| EP4144746A1 (en) | 2014-05-29 | 2023-03-08 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions and uses thereof |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| WO2016036724A1 (en) | 2014-09-02 | 2016-03-10 | The Texas A&M University System | Method of treating organophosphate intoxication |
| HUE051488T2 (hu) | 2014-10-16 | 2021-03-01 | Sage Therapeutics Inc | Készítmények és eljárások központi idegrendszeri rendellenességek kezelésére |
| WO2016061527A1 (en) * | 2014-10-16 | 2016-04-21 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| US10774108B2 (en) | 2014-11-27 | 2020-09-15 | Sage Therapeutics, Inc. | Compositions and methods for treating CNS disorders |
| PL3250210T3 (pl) | 2015-01-26 | 2021-07-26 | Sage Therapeutics, Inc. | Kompozycje i sposoby leczenia zaburzeń OUN |
| CN105985396A (zh) | 2015-02-16 | 2016-10-05 | 苏州泽璟生物制药有限公司 | 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物 |
| JP6875996B2 (ja) | 2015-02-20 | 2021-05-26 | セージ セラピューティクス， インコーポレイテッド | 神経刺激性ステロイド、組成物、およびその使用 |
| UY36741A (es) | 2015-06-21 | 2016-12-30 | Prevacus Inc | Compuesto de esteroide c-20, sus composiciones y usos para tratar la lesión cerebral traumática (tbi), que incluye las conmociones cerebrales |
| JP2018526423A (ja) | 2015-09-08 | 2018-09-13 | ビューポイント セラピューティクス， インコーポレイテッド | 眼科疾患を処置するための化合物および製剤 |
| US10780099B2 (en) | 2015-10-16 | 2020-09-22 | Marinus Pharmaceuticals, Inc. | Injectable neurosteroid formulations containing nanoparticles |
| EP3377070A4 (en) | 2015-11-20 | 2019-07-10 | Sage Therapeutics, Inc. | COMPOUNDS AND METHOD FOR THEIR USE |
| WO2017156103A1 (en) | 2016-03-08 | 2017-09-14 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| US10226550B2 (en) | 2016-03-11 | 2019-03-12 | Brigham Young University | Cationic steroidal antimicrobial compositions for the treatment of dermal tissue |
| ES2992037T3 (es) | 2016-07-11 | 2024-12-05 | Sage Therapeutics Inc | Esteroides neuroactivos sustituidos en C7, C12 y C16 y sus procedimientos de utilización |
| JP7049313B2 (ja) | 2016-07-11 | 2022-04-06 | セージ セラピューティクス， インコーポレイテッド | Ｃ１７、ｃ２０、およびｃ２１置換神経刺激性ステロイドおよびそれらの使用方法 |
| NZ791594A (en) | 2016-08-23 | 2025-08-29 | Sage Therapeutics Inc | A crystalline 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroid |
| US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
| CN108727453A (zh) | 2017-04-20 | 2018-11-02 | 华东理工大学 | 新型pd-1抑制剂及其应用 |
| WO2019018119A1 (en) | 2017-07-18 | 2019-01-24 | Pairnomix, Llc | METHODS FOR TREATING EPILEPSY AND DISORDERS ASSOCIATED WITH KCNTI |
| MX2020001732A (es) | 2017-08-31 | 2020-03-20 | Takeda Pharmaceuticals Co | Tratamiento de las afecciones del sistema nervioso central. |
| EP3678670A1 (en) | 2017-09-07 | 2020-07-15 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
| AU2018364659A1 (en) | 2017-11-10 | 2020-05-28 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treating genetic epileptic disoders |
| CN112823164A (zh) | 2018-05-04 | 2021-05-18 | 阿克罗斯制药公司 | 神经甾体衍生物和其用途 |
| US10562930B1 (en) * | 2018-08-31 | 2020-02-18 | Praxis Precision Medicines, Inc. | Salts and crystal forms of GABAA positive allosteric modulator |
| US10857163B1 (en) * | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
-
2015
- 2015-10-16 WO PCT/US2015/056054 patent/WO2016061527A1/en not_active Ceased
- 2015-10-16 CA CA2964766A patent/CA2964766A1/en active Pending
- 2015-10-16 SG SG11201703073UA patent/SG11201703073UA/en unknown
- 2015-10-16 KR KR1020237042099A patent/KR20230170816A/ko not_active Ceased
- 2015-10-16 RU RU2020131091A patent/RU2020131091A/ru unknown
- 2015-10-16 TW TW104134124A patent/TWI762436B/zh active
- 2015-10-16 BR BR112017007902-0A patent/BR112017007902B1/pt active IP Right Grant
- 2015-10-16 IL IL291533A patent/IL291533B2/en unknown
- 2015-10-16 TW TW112145411A patent/TW202426002A/zh unknown
- 2015-10-16 US US15/519,480 patent/US10577390B2/en active Active
- 2015-10-16 TW TW111104586A patent/TWI869654B/zh active
- 2015-10-16 CN CN202310824285.XA patent/CN117024502A/zh active Pending
- 2015-10-16 CN CN202310812016.1A patent/CN117024501A/zh active Pending
- 2015-10-16 SG SG10202009859YA patent/SG10202009859YA/en unknown
- 2015-10-16 EP EP15851530.4A patent/EP3206494A4/en not_active Withdrawn
- 2015-10-16 RU RU2017116732A patent/RU2733756C2/ru active
- 2015-10-16 PH PH1/2021/550427A patent/PH12021550427A1/en unknown
- 2015-10-16 NZ NZ769008A patent/NZ769008A/en unknown
- 2015-10-16 MX MX2021004492A patent/MX2021004492A/es unknown
- 2015-10-16 CN CN202110184002.0A patent/CN112961206A/zh active Pending
- 2015-10-16 PH PH1/2017/500711A patent/PH12017500711B1/en unknown
- 2015-10-16 AR ARP150103367A patent/AR102306A1/es active IP Right Grant
- 2015-10-16 EP EP24214776.7A patent/EP4527461A3/en active Pending
- 2015-10-16 CN CN202410272424.7A patent/CN118344423A/zh active Pending
- 2015-10-16 JP JP2017520471A patent/JP6909155B2/ja active Active
- 2015-10-16 KR KR1020177013004A patent/KR102612943B1/ko active Active
- 2015-10-16 CN CN201580067540.4A patent/CN107404877A/zh not_active Withdrawn
- 2015-10-16 IL IL315006A patent/IL315006A/en unknown
- 2015-10-16 MX MX2017005002A patent/MX384728B/es unknown
- 2015-10-16 PE PE2017000719A patent/PE20170925A1/es unknown
- 2015-10-16 AU AU2015331749A patent/AU2015331749A1/en not_active Abandoned
- 2015-10-16 SG SG10202009861SA patent/SG10202009861SA/en unknown
- 2015-10-16 EP EP21160969.8A patent/EP3885352B1/en active Active
- 2015-10-16 MY MYPI2017000555A patent/MY190408A/en unknown
- 2015-10-16 CN CN202410278448.3A patent/CN118344424A/zh active Pending
- 2015-10-16 CN CN202110184000.1A patent/CN112940066A/zh active Pending
- 2015-10-18 JO JOP/2015/0257A patent/JO3724B1/ar active
-
2017
- 2017-04-13 IL IL251721A patent/IL251721B/en unknown
- 2017-04-17 MX MX2021008583A patent/MX2021008583A/es unknown
- 2017-05-08 CO CONC2017/0004649A patent/CO2017004649A2/es unknown
-
2018
- 2018-11-30 US US16/206,472 patent/US20190177358A1/en not_active Abandoned
-
2020
- 2020-01-21 US US16/748,117 patent/US11530237B2/en active Active
- 2020-04-30 AU AU2020202892A patent/AU2020202892B2/en active Active
- 2020-05-18 JP JP2020086704A patent/JP7012119B2/ja active Active
-
2021
- 2021-08-19 AU AU2021218132A patent/AU2021218132B2/en active Active
- 2021-10-27 JP JP2021175469A patent/JP7455098B2/ja active Active
-
2022
- 2022-03-15 US US17/694,896 patent/US20220213137A1/en not_active Abandoned
- 2022-03-15 US US17/695,033 patent/US11542297B2/en active Active
- 2022-10-24 US US17/971,865 patent/US12065463B2/en active Active
-
2023
- 2023-03-02 JP JP2023032293A patent/JP7692944B2/ja active Active
-
2024
- 2024-05-03 AU AU2024202959A patent/AU2024202959A1/en not_active Abandoned
- 2024-06-12 US US18/741,425 patent/US20240368213A1/en active Pending
- 2024-08-22 AU AU2024213161A patent/AU2024213161A1/en active Pending